Bioventus Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Claypoole
- Full Time Employees
- 930
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 4721 Emperor Boulevard Durham NC United States of America 27703
- IPO Date
- Feb 11, 2021
- CIK
- 0001665988
- Website
- bioventus.com
- Similar Companies
- Business
- Bioventus Inc. is a global medical technology company specializing in innovations for active healing, operating primarily in the orthobiologics and musculoskeletal healthcare sectors. The company develops and commercializes a diverse portfolio of products segmented into Pain Treatments, Restorative Therapies, and Surgical Solutions. Its product offerings include bone grafts and substitutes, ultrasonic bone healing technologies, bone stimulation devices such as the EXOGEN Bone Healing System, peripheral nerve stimulation for pain management, and surgical orthobiologic solutions targeted at spinal fusion, neurosurgery, and wound care. Bioventus serves healthcare providers and patients across North America, Europe, and other global markets from its headquarters in Durham, North Carolina. Founded in 2001, the company focuses on delivering clinically proven, cost-effective therapies that support musculoskeletal healing and active patient lifestyles. Recent significant company developments include the divestiture of its Advanced Rehabilitation business, Bioness, to Accelmed Partners in late 2024 and early 2025, allowing Bioventus to concentrate on its core active healing segments and improve liquidity. The company has augmented its Pain Treatments portfolio through a distribution agreement with APEX Biologix for the XCELL Platelet-Rich Plasma (PRP) system and has expanded surgical offerings and market reach through the acquisition of Misonix, Inc., which broadened its sales force and enhanced presence in spinal and lower extremity surgical applications. In 2025, Bioventus has actively launched new peripheral nerve stimulation products and focused on strategic margin expansion, operating efficiency, and revenue growth through these initiatives while maintaining a strong cash flow profile. The company continues to leverage synergies across its product lines to drive adoption and growth in musculoskeletal and pain management markets globally.
Bioventus (BVS) Upgraded to Buy: Here's Why
Should Value Investors Buy Bioventus (BVS) Stock?
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
Should Value Investors Buy Bioventus (BVS) Stock?
Are Investors Undervaluing Bioventus (BVS) Right Now?
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Is Bioventus (BVS) Stock Undervalued Right Now?
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?